Mr. Rene Goehrum reports

BIOSYENT SCHEDULES FOURTH QUARTER AND FULL YEAR 2025 EARNINGS RELEASE FOR MARCH 19, 2026

BioSyent Inc. will release its financial results for the fourth quarter and full year ended Dec. 31, 2025, on Thursday, March 19, 2026, after market hours. A presentation on the company's fourth quarter and full-year 2025 results by Rene Goehrum, BioSyent president and chief executive officer, will also be available on the company's website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol RX, BioSyent is a profitable growth-oriented specialty health care company focused on acquiring or in-licensing, marketing and distributing innovative pharmaceutical and oral health products that have been developed, are safe and effective, and have a proven record of improving the lives of patients. BioSyent supports the health care professionals that treat these patients by marketing its products through its Canadian pharma, international pharma and oral health business units.

As of the date of this press release, the company has 11,497,447 common shares outstanding.

We seek Safe Harbor.